Intrathecal Pain Pump: How It Works, Who It Suits, Results
An intrathecal pump delivers medication straight into spinal fluid, so tiny doses do the work of large oral ones. This guide covers candidacy, the trial, the drugs used, refill and maintenance realities, and the complications worth knowing about.
Analyzed Article
This fact-check analysis pertains to a specific external article.
Title: Pain health topic ( Read original article )
Source: U.S. National Library of Medicine
Claim-by-Claim Ledger
| ID | Claim | Risk | Verdict | Evidence | Notes |
|---|---|---|---|---|---|
| C1 | Delivering opioid directly into the intrathecal space achieves analgesia at a small fraction of the equivalent oral dose. | high | supported | V1, V2 | Bypassing systemic circulation is what reduces dose and systemic side effects. |
| C2 | A trial of intrathecal medication is standard practice before permanent pump implantation. | high | supported | V1 | Trial can be a single bolus or a temporary catheter infusion. |
| C3 | Morphine and ziconotide are the medications with the broadest regulatory approval for intrathecal use in chronic pain. | medium | supported | V1, V3 | Other agents and combinations are used off-label under specialist protocols. |
| C4 | Pumps require lifelong maintenance including scheduled refills and eventual battery replacement. | medium | supported | V1 | Missing a refill risks abrupt withdrawal, which can be dangerous. |
| C5 | Intrathecal baclofen is used primarily for severe spasticity rather than for pain alone. | medium | supported | V4 | Pain relief in that setting often follows from reduced spasticity. |
An intrathecal drug delivery system — commonly called a pain pump — is one of the last steps on the chronic pain treatment ladder, and one of the most misunderstood. It does not add a new drug class. It changes the delivery route, putting a very small dose of medication directly into the cerebrospinal fluid where spinal pain receptors sit, instead of sending a much larger dose through the whole body to achieve the same spinal effect [V1][V2]. That single change is why a pump can control pain in someone whose oral medication had reached the limit of tolerable side effects.
Key numbers
- Intrathecal morphine is roughly 100 times more potent than the same drug given orally, so daily doses are measured in milligrams or fractions of a milligram [V2]
- A trial is standard before implant, with success usually defined as about a 50% pain reduction plus functional gain [V1]
- Refills are typically needed every 1–6 months, depending on reservoir size, dose, and concentration [V1]
- Pump batteries generally last several years before replacement surgery [V1]
- Morphine and ziconotide have the broadest approvals for intrathecal chronic pain use [V1][V3]
The two-stage pathway
Stage one is the trial. A bolus or temporary infusion tests whether spinal delivery actually relieves your pain and improves what you can do, with the threshold agreed in advance [V1]. Stage two is implantation under sedation or general anaesthesia: the catheter is threaded into the intrathecal space, tunnelled under the skin, and connected to the pump placed in a pocket in the abdominal wall. Expect a few weeks of incision discomfort, restrictions on bending and lifting, and a period of dose titration in clinic afterwards. Pain control usually improves progressively over the first weeks rather than instantly, because dose finding is deliberately cautious [V1].
Drugs used, and why the choice matters
| Drug | Main role | Notable considerations |
|---|---|---|
| Morphine | First-line intrathecal opioid for chronic pain | Approved; respiratory depression risk during titration [V2] |
| Ziconotide | Non-opioid option, useful when opioids fail | Approved; dizziness, confusion, mood change; slow titration [V3] |
| Hydromorphone / fentanyl | Alternative opioids | Used off-label under specialist protocols [V1] |
| Bupivacaine / clonidine | Added to opioid for neuropathic or refractory pain | Combination therapy; adds hypotension risk [V1] |
| Baclofen | Severe spasticity, with secondary pain relief | Abrupt withdrawal is a medical emergency [V4] |
Living with a pump
The practical realities matter more than most consent conversations suggest. Refill appointments are fixed commitments; long trips need planning around them. MRI is possible with modern devices but requires the pump to be checked and sometimes suspended by the managing team, so tell any imaging department about it. Airport security and dental or surgical procedures are generally fine, but carry the device card. New symptoms — worsening pain despite dose increases, new weakness or numbness, swelling or redness over the pump, or fluid collecting along the catheter — should always be assessed promptly rather than treated with a dose increase, because they can indicate granuloma, infection, or catheter failure [V1][S1].
Red flags: get urgent help
Fever with a stiff neck or headache, redness or discharge at the pump or catheter site, sudden severe withdrawal symptoms such as agitation, sweating, rebound spasticity or high heart rate, new or progressive leg weakness or bladder or bowel dysfunction, or profound drowsiness and slow breathing after any dose change — all require emergency assessment, not a wait-and-see approach [V1][V2][V4].
Pump versus spinal cord stimulator
These are the two implanted options in advanced chronic pain, and they suit different problems. A stimulator modulates nerve signalling with electrical pulses and works best for neuropathic limb pain, such as radicular leg pain or complex regional pain syndrome, with no drug to refill. A pump delivers medication and works across a broader range of pain types — including nociceptive, visceral, and cancer pain — and is often the choice when systemic opioid doses have become intolerable or when pain is diffuse rather than confined to one limb [V1][V9]. Pumps require ongoing refills and carry drug-related risks; stimulators require lead maintenance and can lose effect over time. Some people end up with both, and a trial for each is the fairest way to choose.
Questions worth asking before you consent
Ask what the trial threshold is and what happens if you fall just short of it; what drug and starting dose are planned and why; who manages refills, how far away that clinic is, and what the cover arrangement is when your usual clinician is away; what the expected refill interval is at your likely dose; what happens to your current oral medication after implant, and over what timescale it will be reduced; and what the centre’s own infection and revision rates are [V1]. A service that answers these concretely is one that will manage the device well for the next decade, which matters more than the implant procedure itself [S1].
Related reading: spinal cord stimulator risks and success rates, cancer pain management, non-opioid pain medication options, and chronic pain management complete guide.
Frequently asked questions
How does an intrathecal pain pump work?
A small programmable pump sits under the skin of the abdomen and a fine catheter runs under the skin to the intrathecal space around the spinal cord, so medication reaches spinal pain receptors directly [V1]. Because it bypasses the bloodstream and the blood-brain barrier, the dose needed is a small fraction of the oral equivalent, which is what reduces sedation, constipation, and other systemic effects [V2]. The rate is adjusted wirelessly, and flexible dosing can be programmed for different times of day.
Who is a candidate for a pain pump?
Typically someone with severe chronic pain that has not responded adequately to systemic medication and less invasive interventions, or who cannot tolerate the doses required, and who has passed a successful trial [V1]. It is used in cancer pain, failed back surgery syndrome, and severe spasticity-related pain. Contraindications include active infection, untreated coagulopathy, insufficient body habitus for the device, and unaddressed severe psychiatric illness or substance misuse [V1][V9].
What happens during the trial?
A single intrathecal or epidural bolus, or a temporary catheter infusion over one to several days, is used to see whether the medication meaningfully reduces pain and improves function before committing to an implant [V1]. Success is usually defined in advance — commonly around a 50 percent reduction in pain, plus measurable functional gain and acceptable side effects. A failed trial is useful information: it avoids an implant that would not have helped.
What are the risks and complications?
Early risks include infection, bleeding, spinal headache from cerebrospinal fluid leak, and catheter migration or kinking. Later problems include catheter fracture, pump malfunction, granuloma formation at the catheter tip — which can cause neurological symptoms and needs prompt imaging — and drug-specific effects such as respiratory depression with opioids, or confusion and hallucinations with ziconotide [V1][V2][V3]. Abrupt interruption of intrathecal opioid or baclofen can cause severe withdrawal and is a medical emergency [V4].
How often does the pump need refilling?
Refill intervals depend on reservoir size, concentration, and daily dose, commonly every one to six months, done in clinic with a needle through the skin into the pump port [V1]. Batteries typically last several years, after which the pump is replaced in a minor procedure. Refill appointments are not optional: running the reservoir dry risks abrupt withdrawal, so appointments are scheduled well before the calculated empty date and travel plans need to work around them.
References
- [V1] Bottros MM, Christo PJ. Implantable Intrathecal Drug Delivery System. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [V2] Gonzalez KW, et al. Intrathecal Morphine. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [V3] Schmidtko A, et al. Ziconotide. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [V4] Ghanavatian S, Derian A. Baclofen. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [V9] Dydyk AM, Conermann T. Chronic Pain. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [S1] U.S. National Library of Medicine. Pain health topic. MedlinePlus. 2026. Source . Accessed 2026-08-04.
Editorial Notes
Educational review only. This content is not personalized medical advice, diagnosis, or treatment.
Explore More In This Topic
Looking for additional coverage in this category? Browse all Intrathecal Drug Delivery fact checks.